Results 131 to 140 of about 133,754 (301)

The ITGB2‐COPS3‐SOX2 Axis and SOX2 Liquid‐Liquid Phase Separation: Dual Mechanisms Governing Osteosarcoma Stemness

Advanced Science, EarlyView.
Osteosarcoma stemness is driven by the ITGB2‐COPS3‐SOX2 signaling axis. This study reveals that nuclear COPS3 stabilizes SOX2, which in turn undergoes liquid‐liquid phase separation to promote stemness. Based on this mechanism, a novel COPS3 inhibitor, Z‐5891, was developed, effectively suppressing tumor growth and stemness in vivo, offering a ...
Lei Guo, Zhiqing Zhao, Wei Wang, Jianfang Niu, Bing Wang, Yunfei Lin, Wei Guo, Taiqiang Yan   +7 more
wiley   +1 more source

Immune Checkpoint Inhibitors and Immunomodulators for Cancer Immunotherapy: Insights Into Resistance and Therapeutic Strategies

Advanced Science, EarlyView.
The schematic diagram illustrates the roles of novel immune checkpoints, immunomodulatory factors, cell death and multimodal technologies in cancer immunotherapy. Abstract Cancer immunotherapy has redefined cancer treatment. However, the molecular and cellular basis of immune evasion and therapeutic resistance remains incompletely understood.
Fangquan Chen, Yang Yu, Xiutao Cai, Junhao Lin, Ruirui Liang, Rui Kang, Daolin Tang, Jiao Liu   +7 more
wiley   +1 more source

Surgical and local control outcomes after sequential short-course radiation therapy and chemotherapy for rectal cancer

Surgery Open Science
Background: Total neoadjuvant therapy (TNT) is an accepted approach for the management of locally advanced rectal cancer (LARC) and is associated with a decreased risk of development of metastatic disease compared to standard neoadjuvant therapy. However,
I-Chia Liu, MD, Susan Gearhart, MD MEd, Suqi Ke, MS, Chen Hu, PhD MS, Haniee Chung, MD, Jonathan Efron, MD, Alodia Gabre-Kidan, MD MPH, Peter Najjar, MD MBA, Chady Atallah, MD, Bashar Safar, MD, Eric S. Christenson, MD, Nilofer S. Azad, MD, Valerie Lee, MD, Atif Zaheer, MD, Jacqueline E. Birkness-Gartman, MD, Abhinav V. Reddy, MD, Amol K. Narang, MD, Jeffrey Meyer, MD MS   +17 more
doaj   +1 more source

BZW1 Drives Immune Evasion in Lung Adenocarcinoma via Ferroptosis Suppression

Advanced Science, EarlyView.
BZW1 attenuates ferroptosis by competitively binding NCOA4 and suppress ferrtinophagy‐mediated iron release. The depletion of BZW1 triggers lipid peroxidation through iron homeostasis. Extracellularly, BZW1 attenuates immunogenic cell death and reinvigorates cytotoxic T‐cell responses.
Linyao Zhao, Yue Peng, Qing Liang, Shi Liu, Yang Li, Lei Ma, Menghan Hu, Sujuan Zheng, Zhihua Liu, Shugeng Gao   +9 more
wiley   +1 more source

Neoadjuvant therapy for colorectal cancer from 2015 to 2024: a visual analysis and bibliometric analysis

Frontiers in Oncology
BackgroundColorectal cancer (CRC) imposes a substantial burden on global health., but research trends and hotspots in this field are still not clear.
Boyu Kang, Yihuan Qiao, Jun Zhu, Jun Zhu, Jipeng Li, Jipeng Li   +5 more
doaj   +1 more source

Leveraging Artificial Intelligence and Large Language Models for Cancer Immunotherapy

Advanced Science, EarlyView.
Cancer immunotherapy faces challenges in predicting treatment responses and understanding resistance mechanisms. Artificial intelligence (AI) and machine learning (ML) offer powerful solutions for cancer immunotherapy in patient stratification, biomarker discovery, treatment strategy optimization, and foundation model development.
Xinchao Wu, Mengtao Sun, Lusheng Li, Jieqiong Wang, Shibiao Wan   +4 more
wiley   +1 more source

Comparison of currently common neoadjuvant therapy strategies for rectal cancer: a three-arm retrospective study

Frontiers in Cellular and Infection Microbiology
BackgroundThe evolving neoadjuvant therapy regime is revolutionizing the management of local advanced rectal cancer (LARC). Total neoadjuvant therapy (TNT) and neoadjuvant immunotherapy are currently the most prominent strategies.
Xiao Zhang, Yang An, Yuxin Liu, Ganbin Li, Xiaoyuan Qiu, Yihan Lu, Guole Lin   +6 more
doaj   +1 more source

Total neoadjuvant therapy in rectal cancer – improvement or overtreatment? [PDF]

British Journal of Surgery, 2019
P Mroczkowski, L Dziki
openaire   +2 more sources

Patient‐Derived 3D‐Bioprinted Intrahepatic Cholangiocarcinoma Models Recapitulate Tumor Autologous Traits and Predict Personalized Adjuvant Therapy

Advanced Science, EarlyView.
Leveraging 3D bioprinting, this study establishes patient‐derived in vitro models of intrahepatic cholangiocarcinoma. These models faithfully recapitulate the histopathology, molecular profiles, and genomic characteristics of the original patient tumors.
Yuce Lu, Liwei Du, Minghao Sun, Kai Zhang, Mingchang Pang, Shangze Jiang, Jiaxun Dong, Xiyue Liu, Bao Jin, Fu Xu, Hang Sun, Jiangang Zhang, Huiyu Yang, Xiaobo Yang, Xin Lu, Yiyao Xu, Haitao Zhao, Shunda Du, Xinting Sang, Yongchang Zheng, Lei Zhang, Xueshuai Wan, Huayu Yang, Yilei Mao   +23 more
wiley   +1 more source

Long‐term prognosis is associated with residual disease after neoadjuvant systemic therapy but not with initial nodal status

BJS (British Journal of Surgery), EarlyView., 2020
This long‐term follow‐up study determined survival rates in a Swedish national cohort of 417 patients with breast cancer who all had neoadjuvant systemic therapy (NAST). Sentinel lymph node biopsy (SLNB) was performed before NAST in clinically node‐negative and after NAST in clinically node‐positive patients.
L. Zetterlund, F. Celebioglu, T. Hatschek, J. Frisell, J. de Boniface   +4 more
wiley   +1 more source